Related references
Note: Only part of the references are listed.Deubiquitinase USP35 restrains STING-mediated interferon signaling in ovarian cancer
Jiawen Zhang et al.
CELL DEATH AND DIFFERENTIATION (2021)
Anlotinib as a promising inhibitor on tumor growth of oral squamous cell carcinoma through cell apoptosis and mitotic catastrophe
Zhaoming Deng et al.
CANCER CELL INTERNATIONAL (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
The cross-talk between tumor cells and activated fibroblasts mediated by lactate/BDNF/TrkB signaling promotes acquired resistance to anlotinib in human gastric cancer
Zhijian Jin et al.
REDOX BIOLOGY (2021)
Anlotinib exerts anti-cancer efficiency on lung cancer stem cells in vitro and in vivo through reducing NF-κB activity
Zhuohong Li et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2021)
Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib
Yang Cao et al.
CELL DEATH & DISEASE (2021)
The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis
Juyong Liang et al.
BRITISH JOURNAL OF CANCER (2021)
Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma
Zhexun Huang et al.
JOURNAL OF GENETICS AND GENOMICS (2021)
Anlotinib suppresses metastasis and multidrug resistance via dual blockade of MET/ABCB1 in colorectal carcinoma cells
Lin-Hai Yan et al.
JOURNAL OF CANCER (2021)
anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells
Shaochuan Liu et al.
CELL DEATH & DISEASE (2020)
Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma
Zhi-Ming Wang et al.
CANCER MEDICINE (2020)
Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway
Haoyue Hu et al.
CANCER MANAGEMENT AND RESEARCH (2020)
The forefront of ovarian cancer therapy: update on PARP inhibitors
M. R. Mirza et al.
ANNALS OF ONCOLOGY (2020)
Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade
Qian Yang et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma
Fei Song et al.
CELL DEATH & DISEASE (2020)
Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety
Jing Ni et al.
ONCOTARGETS AND THERAPY (2020)
Transcriptome profiling analysis reveals that ATP6V0E2 is involved in the lysosomal activation by anlotinib
Xin Sun et al.
CELL DEATH & DISEASE (2020)
Reactive oxygen species mediate anlotinib-induced apoptosis via activation of endoplasmic reticulum stress in pancreatic cancer
Liguo Yang et al.
CELL DEATH & DISEASE (2020)
Synergistic Anti-Tumor Activity by Targeting Multiple Signaling Pathways in Ovarian Cancer
Wei Wen et al.
CANCERS (2020)
Treatment of epithelial ovarian cancer
Lindsay Kuroki et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling
Tingting Qin et al.
CANCER BIOLOGY & MEDICINE (2020)
Antitumor effects of anlotinib in thyroid cancer
Xianhui Ruan et al.
ENDOCRINE-RELATED CANCER (2019)
Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma
Gangyang Wang et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells
Lijun Liang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Epithelial ovarian cancer
Stephanie Lheureux et al.
LANCET (2019)
Anlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma
L. Tang et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy
Ming Zhou et al.
CANCER COMMUNICATIONS (2019)
Development of autoimmune pancreatitis is independent of CDKN1A/p21-mediated pancreatic inflammation
Gitta M. Seleznik et al.
GUT (2018)
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
Baohui Han et al.
BRITISH JOURNAL OF CANCER (2018)
Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor
Chengying Xie et al.
CANCER SCIENCE (2018)
Anlotinib inhibits angiogenesis &ITvia&IT suppressing the activation of VEGFR2, PDGFRβ and FGFR1
Binyan Lin et al.
GENE (2018)
PARP inhibitors for targeted treatment in ovarian cancer
Don S. Dizon
LANCET (2017)
p21: A Two-Faced Genome Guardian
Alexandros G. Georgakilas et al.
TRENDS IN MOLECULAR MEDICINE (2017)
Biology of the cell cycle inhibitor p21CDKN1A: molecular mechanisms and relevance in chemical toxicology
Ilaria Dutto et al.
ARCHIVES OF TOXICOLOGY (2015)
Share Paper
